Skandinaviska Enskilda Banken Ab (Publ) Immunity Bio, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $21.5 Billion
- Q3 2024
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 270,950 shares of IBRX stock, worth $712,598. This represents 0.0% of its overall portfolio holdings.
Number of Shares
270,950
Previous 270,950
-0.0%
Holding current value
$712,598
Previous $1.71 Million
41.3%
% of portfolio
0.0%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding IBRX
# of Institutions
204Shares Held
70MCall Options Held
1.68MPut Options Held
1.31M-
Vanguard Group Inc Valley Forge, PA16.9MShares$44.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$30 Million0.0% of portfolio
-
State Street Corp Boston, MA8.65MShares$22.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.85MShares$10.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.25MShares$5.91 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $1.05B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...